HCG: Human Chorionic Gonadotropin Reference Standards, Fertility Research Applications & 2026 Supply Status

What Is HCG?

Human chorionic gonadotropin (HCG) is a heterodimeric glycoprotein hormone produced by the syncytiotrophoblast of the placenta during pregnancy. Structurally it consists of a 92-amino-acid alpha subunit — shared identically with luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH) — non-covalently associated with a 145-amino-acid beta subunit that carries the hormone-specific information.^[4] The mature heterodimer is roughly 36-40 kDa depending on glycosylation, with up to eight N- and O-linked carbohydrate side chains. Those chains are not decorative: they extend circulating half-life relative to LH and they modulate receptor signalling bias.

The beta-HCG subunit shares approximately 80% sequence homology with the LH beta subunit, with a unique C-terminal peptide extension of 24 amino acids carrying additional O-linked glycans. That homology is the reason HCG and LH both engage the same receptor on the gonadal cell surface — and the reason a beta-HCG immunoassay is the diagnostic backbone of pregnancy testing in clinical chemistry. For research-reference purposes, the practical consequence is that HCG behaves as a long-acting LH agonist with greater receptor occupancy than endogenous LH at equivalent molar concentrations.

Unlike short peptides such as KPV or growth-hormone-axis molecules like the CJC-1295 + Ipamorelin blend, HCG is not gravimetrically quantified for research handling. It is measured in international units (IU) calibrated against the WHO 5th International Standard for Chorionic Gonadotropin (NIBSC 07/364), because biological potency depends on glycosylation and the presence or absence of nicked subunits, not simply on peptide mass.^[5]

Mechanism: LH/CG Receptor Activation & Downstream Steroidogenesis

HCG and LH share a single receptor — the LH/choriogonadotropin receptor (LHCGR) — a class A G-protein-coupled receptor with a large extracellular leucine-rich repeat domain that binds the heterodimeric hormone with sub-nanomolar affinity. The receptor is expressed primarily on Leydig cells in the male testis and on theca and granulosa cells in the female ovary, with smaller populations described in the uterus, placenta, and fetal tissues.^[4]

The canonical signalling cascade is well characterised:

• Gs-coupled cAMP/PKA activation. HCG binding triggers receptor coupling to Gαs, adenylyl cyclase activation, and a rise in intracellular cAMP. PKA then phosphorylates downstream targets including the steroidogenic acute regulatory protein (StAR), which controls cholesterol transport into the inner mitochondrial membrane — the rate-limiting step of steroid hormone synthesis.
• Leydig-cell testosterone induction. In males, cAMP-driven StAR activation increases conversion of cholesterol to pregnenolone via the CYP11A1 (P450scc) enzyme, with downstream flux through 17α-hydroxylase, 17,20-lyase, 3β-HSD, and 17β-HSD to testosterone. HCG stimulation produces a measurable serum testosterone rise within hours in research-reference protocols.
• Ovarian steroidogenesis and ovulation triggering. In females, HCG drives theca-cell androgen production (substrate for granulosa-cell aromatization to estradiol) and, at the LH-surge-equivalent dose used in assisted reproduction, triggers final oocyte maturation and follicular rupture.
• Secondary Gq/PLC signalling at higher concentrations. The LH/CG receptor also couples to Gq at higher ligand occupancy, producing inositol triphosphate and diacylglycerol second messengers and contributing to receptor desensitization kinetics that differ from LH because of HCG's longer half-life and greater receptor occupancy time.

A practical research-reference point: HCG's pharmacokinetic profile — circulating half-life of roughly 24-36 hours after intramuscular administration of urinary-derived product, compared to LH's roughly 20-minute half-life — is the reason single-dose HCG protocols are used to mimic an LH surge in fertility research, and why repeat-dose protocols produce sustained Leydig-cell stimulation rather than the pulsatile pattern that endogenous LH provides.

Recombinant vs Urinary-Derived HCG: Pregnyl, Novarel, Ovidrel

Three product lines dominate the global HCG supply, and the differences matter for research-reference comparability.

The biological case for recombinant choriogonadotropin alfa (Ovidrel) is straightforward: a defined CHO-cell expression system produces a more homogeneous glycoform population than urine-extracted material, with batch-to-batch variability constrained by manufacturing controls rather than donor urine composition. The trade-off is that the 250 mcg pre-filled syringe is a fixed, non-divisible unit, which constrains protocol flexibility relative to a reconstitutable lyophilized vial.

For research-reference comparability, the urinary-derived products carry a heterogeneous glycoform mix that includes nicked and hyperglycosylated species; this heterogeneity is exactly what the IU-based potency standard exists to control. Equating "5,000 IU urinary HCG" with "5,000 IU recombinant HCG" on the basis of label alone, without bioassay-anchored equivalence, is the classic error in cross-product research design.

Fertility Research Applications & the APHRODITE Criteria (Andrology 2026)

HCG's most extensively studied research application is male infertility, specifically the management of secondary hypogonadism and the stratification of men with non-obstructive azoospermia (NOA) who may benefit from gonadotropin-based fertility therapy. Esteves and colleagues published an expert review in Andrology (2026) introducing the APHRODITE criteria — Andrological Phenotypic Reproductive Outcomes after DIagnostic Testing and Endocrinological evaluation — as a stratification framework for NOA.^[1]

The framework formalises a separation that has long been informal in andrology practice: men whose azoospermia reflects insufficient pituitary drive (secondary hypogonadism, characterised by low FSH, low or low-normal LH, low testosterone, and preserved testicular volume) versus men whose azoospermia reflects primary testicular failure (elevated FSH, elevated LH, low testosterone, and reduced testicular volume). The first group is the subset in which HCG and HCG + recombinant FSH protocols have the strongest published response signal; the second group has a markedly weaker response and benefits more from surgical sperm-retrieval pathways.

Esteves et al. argue that explicit APHRODITE stratification at intake reduces the long-standing problem of mixed-aetiology NOA cohorts in published trials, where outcome variance has been inflated by including patients with very different underlying pathology. For research-reference purposes, this is the most important methodological development in HCG fertility research in the current cycle: future trial data and meta-analyses are likely to report results within APHRODITE strata rather than across an undifferentiated NOA population.^[1]

Adjacent endocrine-axis research-reference material on this site covers tesamorelin (GHRH analog) and the CJC-1295 + Ipamorelin GH-secretagogue blend as separate hypothalamic-pituitary axes; HCG sits on the hypothalamic-pituitary-gonadal axis and is not interchangeable with growth-hormone-axis tools.

Post-Androgen Spermatogenesis Recovery — Smit et al. 2025

A second 2020s-era data stream centres on men presenting with azoospermia or severe oligozoospermia following non-prescribed androgen use. Exogenous androgen suppresses hypothalamic GnRH, collapsing pituitary LH and FSH output and, secondarily, intratesticular testosterone and spermatogenesis. Recovery after discontinuation is variable and often incomplete; HCG-based protocols are the most-published pharmacological intervention in this space.

Smit, Verdegaal, and Bond and colleagues reported a retrospective real-world cohort in F&S Reports (2025) describing HCG-based regimens in men presenting to a fertility clinic following non-prescribed androgen use. The cohort reported a meaningful proportion of patients achieving spermatogenesis recovery on HCG or HCG-plus-recombinant-FSH protocols, with recovery time varying with baseline testicular volume and duration of prior androgen exposure.^[2]

Two interpretive cautions apply for a research-reference reader. First, retrospective fertility-clinic cohorts select for a population motivated to recover fertility — generalisation to all post-androgen presentations is unsupported. Second, the published data describe outcomes inside a regulated clinical setting; nothing in the published paper supports a self-administered "post-cycle" framing, and Remy Peptides does not provide such framing on any catalog or research page.

The honest summary across the published record is consistent: HCG has reproducible mechanistic and clinical evidence in fertility research, with the strongest signal in well-stratified secondary-hypogonadism and post-androgen-suppression populations. It is not framed here for human use.

U.S. Supply Status & the BPCIA Reclassification

The single most consequential regulatory event in modern HCG supply is the March 23, 2020 reclassification of HCG from a small-molecule drug to a biologic under the Biologics Price Competition and Innovation Act (BPCIA). The reclassification was part of a broader FDA "deemed to be a license" transition that moved a defined set of protein products — including HCG, insulin, and others — from the 505(b) drug pathway to the 351(a) biologics pathway. The intent was regulatory rationalisation; the supply consequence was severe.^[3]

Three downstream effects defined the post-2020 HCG market:

• Loss of 503A compounding pharmacy access. HCG, as a biologic, no longer qualified as a bulk ingredient that 503A compounding pharmacies could routinely use. A large segment of community-pharmacy HCG access collapsed overnight on March 23, 2020.
• Branded urinary-derived products entered intermittent shortage. Pregnyl and Novarel, both urinary-derived, transitioned into the BPCIA framework as legacy biologics and have shown recurring shortage and reactivation cycles every year since 2020. The FDA Drug Shortage List has carried HCG continuously through 2026 — now the sixth consecutive year of shortage status.
• Recombinant Ovidrel emerged as the most stable supply. Choriogonadotropin alfa, manufactured in a controlled CHO-cell expression process, has maintained the most consistent availability among approved HCG products through the shortage period, and dominates the assisted-reproduction protocol space in 2026 as a result.

For UAE research-reference purposes, the U.S. regulatory situation is informational rather than directly governing — UAE chorionic gonadotropin supply is independent of FDA shortage designations — but the global manufacturing concentration created by the BPCIA transition affects upstream availability of urinary-derived material worldwide. This is the structural reason Remy Peptides does not publish a fixed restock ETA for the HCG 5000 IU research-reference vial: the supply chain is intermittent at the source.

Reconstitution & Storage Protocol

HCG handling follows the standard lyophilized-glycoprotein research-reference protocol, with one critical convention that separates it from most other peptides in this library.

1. IU measurement, not mg

All reconstitution math for HCG should be done in international units, not milligrams. The label on a 5,000 IU vial is the bioassay-anchored unit; converting to a milligram or microgram equivalent for protocol design is the wrong abstraction and reliably produces cross-product mismatches. A short discussion of unit conversion sits in the reconstitution calculator for the molecules that do use mg labelling; HCG is intentionally not represented there in mg form for this reason.

2. Bacteriostatic water reconstitution

Lyophilized HCG is typically reconstituted with bacteriostatic water (0.9% benzyl alcohol in sterile water) for research-reference purposes. The volume of diluent determines the resulting IU/mL concentration: 1 mL of bacteriostatic water added to a 5,000 IU vial yields 5,000 IU/mL; 5 mL yields 1,000 IU/mL. Vial mixing should be by gentle swirling, never vortexing, to avoid mechanical denaturation of the glycoprotein.

3. Cold-chain after reconstitution

Reconstituted HCG is unstable at room temperature and should be stored at 2-8°C with use within roughly 30-60 days of reconstitution depending on diluent and vial integrity. Lyophilized HCG, by contrast, is significantly more stable: published manufacturer data support multi-year stability for properly sealed lyophilized vials under refrigeration. The catalog vial ships with cold-chain handling per the practice documented across the COA library.

4. Glycoprotein-specific handling

Repeated freeze-thaw cycles degrade glycoprotein activity disproportionately to peptide bond cleavage — alpha/beta subunit dissociation is the dominant failure mode, and a reconstituted HCG solution that has been frozen and thawed once should be treated as having reduced potency even if no visible precipitation has occurred. Single-use aliquoting at reconstitution is the standard research-reference practice for this reason.

HCG Research Access in Dubai & UAE — Currently Out of Stock

Remy Peptides lists the HCG 5000 IU research-reference vial in the UAE catalog as an IU-keyed lyophilized chorionic gonadotropin format with cold-chain handling under UAE MoHAP Circular 17/2022. The line is currently out of stock.

No restock date is published, deliberately. The global chorionic gonadotropin supply chain has been intermittent at the source since the 2020 BPCIA reclassification described above, and a fixed restock ETA cannot be honestly committed against that upstream pattern. The product page exposes a restock-alert flow that captures researcher email addresses and notifies the list when the line returns; researchers can also message the WhatsApp line at +351 924 694 686 for the current ETA. Reference pricing of AED 250-300 per vial is held for when stock returns. The page is maintained as a research-reference listing during the OOS window rather than removed.

Adjacent endocrine-axis research-reference compounds that are typically in catalog include the CJC-1295 + Ipamorelin GH-secretagogue blend and the tesamorelin GHRH analog; both sit on the hypothalamic-pituitary axis but are not substitutes for HCG, which is the only listed compound on the hypothalamic-pituitary-gonadal axis in the current catalog.

For research-reference handling and compliance context, see the COA library for the published batch-evidence pattern that ships with restocked lines, and the reconstitution calculator for the broader peptide-handling tooling on this site.